Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Acts as a growth inhibitor. Zusätzlich bieten wir Ihnen Transforming Growth Factor beta Regulator 1 Antikörper (38) und viele weitere Produktgruppen zu diesem Protein an.
Showing 6 out of 6 products:
NIAM down-regulation in vivo results in a significant predisposition to developing benign tumors or early stage cancers.
novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2 (zeige MDM2 Proteine)-p53 (zeige TP53 Proteine) signaling
In primary B-cell lymphoma NIAM-positive cases have significant lower levels of miR (zeige MLXIP Proteine)-155 as compared to NIAM-negative cases, suggesting that NIAM is regulated by miR (zeige MLXIP Proteine)-155 in primary B-cell lymphoma.
NIAM regulates 2 critical pathways that control p53 (zeige TP53 Proteine) function and are altered in human cancers, implying an important role for NIAM in tumorigenesis.
Sructure of a fragment of TBRG1 was shown to encompasses two motifs. The FYRN and FYRC regions each form part of a single folded module (the FYR (zeige FZR1 Proteine) domain), which adopts a novel alpha + beta fold.
NIAM is a nuclear interactor of ARF and Mdm2
Acts as a growth inhibitor. Can activate p53/TP53, causes G1 arrest and collaborates with CDKN2A to restrict proliferation, but does not require either protein to inhibit DNA synthesis. Redistributes CDKN2A into the nucleoplasm. Involved in maintaining chromosomal stability.
transforming growth factor beta regulator 1
, transforming growth factor beta regulator 1-like
, nuclear interactor of ARF and Mdm2
, nuclear interactor of ARF and MDM2
, transforming growth factor beta regulated gene 1